Also, importantly, the identification of novel downstream targets in the AKT/FOXO pathway opens the possibility of new therapeutic targets in treatment of cardiac dysfunction, hyperglycemia and hypertriglyceridemia. Here, AKT1 is linked to Hyperglycemia.